NewsBenzingaNektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M Benzinga 2026.11.12 21:17 (GMT+0) Open on Benzinga Other news Stocks Settle Lower on Nvidia Rout and Higher Crude and Bond Yields Jensen Huang’s Exit Will Test AI’s Stocks, and Great-Man Theory As Data Center Concerns Hit CRWV Stock After the Midterms, CoreWeave Is Going Straight to Texas’s Governor-Elect Dynatrace, Inc. (DT) Presents at BMO Capital Technology and Innovation Leaders Conference Transcript BK Technologies Corporation (BKTI) Q3 2026 Earnings Call Transcript Aveanna Healthcare Holdings Inc. (AVAH) Q3 2026 Earnings Call Transcript
As Data Center Concerns Hit CRWV Stock After the Midterms, CoreWeave Is Going Straight to Texas’s Governor-Elect
